Not Yet RecruitingPhase 4ACTRN12609000072213

Comparison of 0.5mg/kg and 1.0mg/kg Suxamethonium in patients undergoing Electroconvulsive Therapy (ECT)

Comparison of 0.5mg/kg and 1mg/kg Suxamethonium in patients undergoing voluntary ECT(Electroconvulsive Therapy)

Sponsor

Peninsula Health

Enrollment

50 participants

Start Date

Feb 1, 2009

Study Type

Interventional

Conditions

the incidence and severity of postprocedure myalgia after ECT comparing two different doses of muscle relaxant compare the amount of post therapy myalgia between the two dosage groups patient undergoing voluntary ECT.

Summary

Patients undergoing ECT often experience postprocedure myalgia. There is also a published range of muscle relaxant doses to minimise this occurrence. It is the purpose of this study to compare the higher and lower recommended doses to see if there is a difference in postprocedure myalgia between the two doses.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 80 Yearss

Inclusion Criteria1

voluntary patients already booked independently for ECT

Exclusion Criteria2

involuntary patient or patients deemed
unable to give consent

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

comparison two doses of suxamethonium in ECT. suxamethonium is a muscle relaxant administered intravenously at the time of ECT to reduce muscle spasms. It will be administered in this way on two consecutive occasions within a week of each other at the time of ECT. On one occassion, the dosage amount of Suxamethonium administered to participants will be 1.0mg/kg

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12609000072213